Via genome-wide shRNA screening, Guangyuan Kan and his colleagues [26] identified DKC1 as a molecular driver in colorectal cancer progression and they then proved the therapeutic efficiency of synergistic inhibition of DKC1 and MEK1/2 in fighting tumor. This evidence concerns the gene MAP2K1 and colorectal cancer.